Insider · CIK 0001883804
Conley Chee
Files at SYRS (Syros Pharmaceuticals, Inc.). First filing Nov 20, 2024, latest Nov 20, 2024.
In brief
Conley Chee files SEC Form 4 as CEO, president and director at SYRS (Syros Pharmaceuticals, Inc.). Since Nov 20, 2024, Conley Chee has reported 0 open-market buys worth $0 and 1 open-market sell worth $27k, the latest filed on Nov 20, 2024.
A track record needs three past buys with six months of prices behind them; Conley Chee has 0, so none is measured yet.
The newest scored trade: sold $27k of SYRS on Nov 18, 2024, filed Nov 20, 2024, scored 65 (notable).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SYRS: Syros Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 65Notable | Syros Pharmaceuticals, Inc. | $27k 134,797 shares | -100% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 18, 2024 | SYRS Syros Pharmaceuticals, Inc. | 100,000 0.37% of outstanding | $26k | Nov 18, 2024 | $18k |
| Nov 18, 2024 | SYRS Syros Pharmaceuticals, Inc. | 30,797 0.11% of outstanding | $6,139 | Nov 18, 2024 | $18k |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | SYRS Syros Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -134,797 | $0.20 | $27k | 0 | Nov 20, 2024 |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +17,000 | - | - | 139,504 | Nov 4, 2024 |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | FTax withholding Common Stock10b5-1 | -8,707 | $2.09 | $18k | 130,797 | Nov 4, 2024 |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -17,000 | $0.00 | $0 | 0 | Nov 4, 2024 |
| Dec 2, 2023 | SYRS Syros Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +86,000 | $0.00 | $0 | 86,000 | Dec 5, 2023 |
| Oct 31, 2023 | SYRS Syros Pharmaceuticals, Inc. | MOption exercise Common Stock | +17,000 | - | - | 18,342 | Nov 2, 2023 |
| Nov 1, 2023 | SYRS Syros Pharmaceuticals, Inc. | FTax withholding Common Stock | -6,004 | $2.22 | $13k | 12,338 | Nov 2, 2023 |
| Oct 31, 2023 | SYRS Syros Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -17,000 | $0.00 | $0 | 17,000 | Nov 2, 2023 |
Questions about Conley Chee
Answered from the filings on this page, as of the latest one.
Is Conley Chee buying or selling?
Not in the last 12 months. Conley Chee's latest open-market trade on SEC Form 4 was sold $27k of SYRS on Nov 18, 2024.
How did Conley Chee's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Conley Chee has 0.
Where does Conley Chee file Form 4?
Conley Chee has filed Form 4 at SYRS (Syros Pharmaceuticals, Inc.) as President & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.